← Leaderboards
Bryan C Jensen
Seattle Biomedical Research Institute
$1,416,469
Attributed
$1,564,257
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $471.3K · FY2018–22$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,564,257 · 3
By mechanism
R21$1,564,257 · 3
Top collaborators
- Marilyn Parsons2 shared
Most similar at Seattle Biomedical Research Institute
Same institution · by research overlap
- Peter John Myler$6,677,839
- Marilyn Parsons$15,453,740
Others in their field
Other Emerging Leaders on “Pathogen”
- Scott Hensley · University Of Pennsylvania$49,758,212
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$49,703,204
- Thomas Denny · Duke University$42,477,454
- Ryan Cirz · Revagenix, Inc.$40,209,479
- Sujatha Rashid · American Type Culture Collection$37,889,194
- Bala Raja · Luminostics, Inc.$28,624,460
Research focus
PathogenNeglectLeishmaniasisBindingLeishmaniaLesionNovel TherapeuticsPathogenicityGenesCutaneousLeishmania InfantumAfrican TrypanosomiasisAnalogLeishmania DonovaniKinase InhibitorLeftInhibitor/AntagonistChagas DiseaseBinding SitesInsectaDrug TargetingBaseAmino AcidsCells
Grant awards (7)
de novo creation of base J in Leishmania$235,625
R21 · FY2022 · AI · contact PI
de novo creation of base J in Leishmania$282,750
R21 · FY2021 · AI · contact PI
Identification of essential kinases in Leishmania$279,000
R21 · FY2020 · AI · contact PI
Protein kinase AEK1 as a T. brucei drug target and its potential in other trypanosomatids$238,806
R21 · FY2019 · AI · contact PI
Identification of essential kinases in Leishmania$232,500
R21 · FY2019 · AI · contact PI
Protein kinase AEK1 as a T. brucei drug target and its potential in other trypanosomatids$227,069
R21 · FY2018 · AI
Protein kinase AEK1 as a T. brucei drug target and its potential in other trypanosomatids$68,507
R21 · FY2018 · AI